Clinical implications for substandard, nonproprietary medicines in multiple sclerosis: focus on fingolimod.

Correale J, Chiquete E, Boyko A, Beran RG, Strauch J B, Milojevic S, Frider N

Drug Des Devel Ther. 2016; 10:2109-17. Epub 2016 Jun 30. PMID: 27418809. Abstract